From day one, as evidenced in my earliest posts, my investment in RVV was always a long term one, ie, the Covid angle was a nice added bonus.
Although Buc's FDA approval will be a major boost for the company, enabling them to accelerate the development of the Psych business, for me it's not the "be all, end all".
As I've noted on many occasions, most of the NOISE about our current stagnation comes from investors looking to cash in asap, and while I take no issue with that mindset, I don't accept the overly gloomy perception being promoted as a result.
Mind you, even though Covid seems to winding down, I'd prefer that comprehensive Buc data is compiled now since viral outbreaks seems to be an ever evolving issue and who knows when the next one will appear.
As a prophylactic and/or therapeutic Buc, IMO, seems to still have some legs in it based on what is being currently reported per recovery rates and lingering effects which it may or may not remedy to some extent.
I guess we'll see in a few months...................
News 
Market Data 
Discover 
AI
